OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria
Sebastiaan C. Goulooze, Nelleke Snelder, Andreas Seelmann, et al.
Clinical Pharmacokinetics (2021) Vol. 61, Iss. 3, pp. 451-462
Open Access | Times Cited: 24
Sebastiaan C. Goulooze, Nelleke Snelder, Andreas Seelmann, et al.
Clinical Pharmacokinetics (2021) Vol. 61, Iss. 3, pp. 451-462
Open Access | Times Cited: 24
Showing 24 citing articles:
Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus
Ruolin Lv, Lili Xu, Lin Che, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 27
Ruolin Lv, Lili Xu, Lin Che, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 27
Finerenone: From the Mechanism of Action to Clinical Use in Kidney Disease
Nejc Piko, Sebastjan Bevc, Radovan Hojs, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 4, pp. 418-418
Open Access | Times Cited: 7
Nejc Piko, Sebastjan Bevc, Radovan Hojs, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 4, pp. 418-418
Open Access | Times Cited: 7
Efficacy and Safety of Finerenone in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Mingzhu Zhang, Wujisiguleng Bao, Qiyan Zheng, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 27
Mingzhu Zhang, Wujisiguleng Bao, Qiyan Zheng, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 27
Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes
Edgar V. Lerma, Daniel J. Wilson
Expert Review of Clinical Pharmacology (2022) Vol. 15, Iss. 5, pp. 501-513
Open Access | Times Cited: 26
Edgar V. Lerma, Daniel J. Wilson
Expert Review of Clinical Pharmacology (2022) Vol. 15, Iss. 5, pp. 501-513
Open Access | Times Cited: 26
Association between various dosage forms of semaglutide and ocular adverse events in a real-world setting
Tao Zhao, Liting Zheng, Yiyun Feng, et al.
BMC Ophthalmology (2025) Vol. 25, Iss. 1
Open Access
Tao Zhao, Liting Zheng, Yiyun Feng, et al.
BMC Ophthalmology (2025) Vol. 25, Iss. 1
Open Access
The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
Roland Heinig, Thomas Eißing
Clinical Pharmacokinetics (2023) Vol. 62, Iss. 12, pp. 1673-1693
Open Access | Times Cited: 9
Roland Heinig, Thomas Eißing
Clinical Pharmacokinetics (2023) Vol. 62, Iss. 12, pp. 1673-1693
Open Access | Times Cited: 9
Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO‐DKD and FIDELIO‐DKD
Thomas Eißing, Sebastiaan C. Goulooze, Paul van den Berg, et al.
Diabetes Obesity and Metabolism (2023) Vol. 26, Iss. 3, pp. 924-936
Open Access | Times Cited: 9
Thomas Eißing, Sebastiaan C. Goulooze, Paul van den Berg, et al.
Diabetes Obesity and Metabolism (2023) Vol. 26, Iss. 3, pp. 924-936
Open Access | Times Cited: 9
Non-steroidal mineralocorticoid antagonists and hyperkalemia monitoring in chronic kidney disease patients associated with type II diabetes: a narrative review
Javier Morales, Biff F. Palmer
Postgraduate Medicine (2024) Vol. 136, Iss. 2, pp. 111-119
Open Access | Times Cited: 3
Javier Morales, Biff F. Palmer
Postgraduate Medicine (2024) Vol. 136, Iss. 2, pp. 111-119
Open Access | Times Cited: 3
Dose–Exposure–Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD
Sebastiaan C. Goulooze, Hiddo J.L. Heerspink, Martijn van Noort, et al.
Clinical Pharmacokinetics (2022) Vol. 61, Iss. 7, pp. 1013-1025
Open Access | Times Cited: 14
Sebastiaan C. Goulooze, Hiddo J.L. Heerspink, Martijn van Noort, et al.
Clinical Pharmacokinetics (2022) Vol. 61, Iss. 7, pp. 1013-1025
Open Access | Times Cited: 14
The drug titration paradox: more drug does not correlate with more effect in individual clinical data
Thomas W. Schnider, Charles F. Minto, Martin Luginbühl, et al.
British Journal of Anaesthesia (2022) Vol. 129, Iss. 6, pp. 861-867
Open Access | Times Cited: 14
Thomas W. Schnider, Charles F. Minto, Martin Luginbühl, et al.
British Journal of Anaesthesia (2022) Vol. 129, Iss. 6, pp. 861-867
Open Access | Times Cited: 14
The role of a novel mineralocorticoid receptor antagonist, finerenone, in chronic kidney disease: mechanisms and clinical advances
Xinping Chen, Xuan Li, Kexin Zhang, et al.
Clinical and Experimental Nephrology (2023) Vol. 28, Iss. 2, pp. 125-135
Closed Access | Times Cited: 8
Xinping Chen, Xuan Li, Kexin Zhang, et al.
Clinical and Experimental Nephrology (2023) Vol. 28, Iss. 2, pp. 125-135
Closed Access | Times Cited: 8
Physiologically‐based pharmacokinetic modeling to predict CYP3A4‐mediated drug‐drug interactions of finerenone
Thomas Wendl, Sebastian Frechen, Michael Gerisch, et al.
CPT Pharmacometrics & Systems Pharmacology (2021) Vol. 11, Iss. 2, pp. 199-211
Open Access | Times Cited: 16
Thomas Wendl, Sebastian Frechen, Michael Gerisch, et al.
CPT Pharmacometrics & Systems Pharmacology (2021) Vol. 11, Iss. 2, pp. 199-211
Open Access | Times Cited: 16
Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis
Paul van den Berg, Martijn Ruppert, Emir Mešić, et al.
Clinical Pharmacokinetics (2021) Vol. 61, Iss. 3, pp. 439-450
Open Access | Times Cited: 15
Paul van den Berg, Martijn Ruppert, Emir Mešić, et al.
Clinical Pharmacokinetics (2021) Vol. 61, Iss. 3, pp. 439-450
Open Access | Times Cited: 15
Overview of the safety, efficiency, and potential mechanisms of finerenone for diabetic kidney diseases
Wen‐Ming Chen, Lingqian Zheng, Jiali Wang, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 5
Wen‐Ming Chen, Lingqian Zheng, Jiali Wang, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 5
Effects of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, on Cardiovascular Disease, Chronic Kidney Disease, and Blood Pressure
Jonathan D. Ravid, Luke J. Laffin
Current Cardiology Reports (2022) Vol. 24, Iss. 10, pp. 1251-1259
Closed Access | Times Cited: 8
Jonathan D. Ravid, Luke J. Laffin
Current Cardiology Reports (2022) Vol. 24, Iss. 10, pp. 1251-1259
Closed Access | Times Cited: 8
Nonsteroidal Mineralocorticoid Receptor Antagonist Eliciting Cardiorenal Protection Is a New Option for Patients with Chronic Kidney Disease
Wenyu Liu, Shengqiang Yu
Kidney Diseases (2022) Vol. 9, Iss. 1, pp. 12-25
Open Access | Times Cited: 7
Wenyu Liu, Shengqiang Yu
Kidney Diseases (2022) Vol. 9, Iss. 1, pp. 12-25
Open Access | Times Cited: 7
Finerenone and diabetic renal disease: a narrative review
Kirthika Venkatesan, Mabel Mary James Cheryeth, Anna Tintu Verghese, et al.
Endocrine (2024) Vol. 86, Iss. 3, pp. 882-889
Closed Access | Times Cited: 1
Kirthika Venkatesan, Mabel Mary James Cheryeth, Anna Tintu Verghese, et al.
Endocrine (2024) Vol. 86, Iss. 3, pp. 882-889
Closed Access | Times Cited: 1
Post-marketing safety of finerenone: a disproportionality analysis of the FDA adverse event reporting system
Yiyi Jin, Miao Fan, Xiaomeng Zheng, et al.
Expert Opinion on Drug Safety (2024), pp. 1-6
Closed Access | Times Cited: 1
Yiyi Jin, Miao Fan, Xiaomeng Zheng, et al.
Expert Opinion on Drug Safety (2024), pp. 1-6
Closed Access | Times Cited: 1
Finerenone: Will It Be a Game-changer?
Dinesh Khullar, Anish Kumar Gupta, Kulwant Singh
Cardiac failure review (2024) Vol. 10
Open Access | Times Cited: 1
Dinesh Khullar, Anish Kumar Gupta, Kulwant Singh
Cardiac failure review (2024) Vol. 10
Open Access | Times Cited: 1
Finerenone: a new mineralocorticoid receptor antagonist to beat chronic kidney disease
R. Raj
Current Opinion in Nephrology & Hypertension (2022) Vol. 31, Iss. 3, pp. 265-271
Closed Access | Times Cited: 6
R. Raj
Current Opinion in Nephrology & Hypertension (2022) Vol. 31, Iss. 3, pp. 265-271
Closed Access | Times Cited: 6
Optimization of potassium management in patients with chronic kidney disease and type 2 diabetes on finerenone
Alberto Ortíz, Roberto Alcázar Arroyo, Pedro Pablo Casado Escribano, et al.
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 6, pp. 519-531
Closed Access | Times Cited: 3
Alberto Ortíz, Roberto Alcázar Arroyo, Pedro Pablo Casado Escribano, et al.
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 6, pp. 519-531
Closed Access | Times Cited: 3
Pharmacokinetic and Pharmacodynamic Interaction of Finerenone with Diltiazem, Fluconazole, and Ritonavir in Rats
Tham Thi Bui, Sohyeon Kim, Woo Jin Jung, et al.
European Journal of Drug Metabolism and Pharmacokinetics (2024) Vol. 49, Iss. 6, pp. 701-714
Closed Access
Tham Thi Bui, Sohyeon Kim, Woo Jin Jung, et al.
European Journal of Drug Metabolism and Pharmacokinetics (2024) Vol. 49, Iss. 6, pp. 701-714
Closed Access
Finerenone and diabetic renal disease: a narrative review
Kirthika Venkatesan, Mabel Mary James Cheryeth, Anna Tintu Verghese, et al.
Journal of Prescribing Practice (2024) Vol. 6, Iss. 11, pp. 474-480
Closed Access
Kirthika Venkatesan, Mabel Mary James Cheryeth, Anna Tintu Verghese, et al.
Journal of Prescribing Practice (2024) Vol. 6, Iss. 11, pp. 474-480
Closed Access
Research progress in anti-renal fibrosis drugs.
Hanwei Huang, Zhangzhe Peng, Qiongjing Yuan
PubMed (2024) Vol. 49, Iss. 8, pp. 1353-1362
Closed Access
Hanwei Huang, Zhangzhe Peng, Qiongjing Yuan
PubMed (2024) Vol. 49, Iss. 8, pp. 1353-1362
Closed Access
